GlassScriptPhysician profile
Glenn D Wong
NPI 1063537934
$974.22
in general payments reported to CMS, 2019-2025
22 companies · $339 in 2025
The $339 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16.75 · 2020: $13.37 · 2021: $23.94 · 2022: $37.87 · 2023: $44.66 · 2024: $498 · 2025: $339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $882.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $882.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $102.93 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $80.27 | 2024-2025 | Opdivo |
| Merck Sharp & Dohme LLC | $72.98 | 2020-2025 | Keytruda, Welireg, Lynparza |
| Janssen Biotech, INC. | $71.92 | 2023-2025 | Rybrevant, Akeega, Erleada |
| Celgene Corporation | $66.90 | 2024 | Reblozyl |
| Acrotech Biopharma INC. | $61.81 | 2021-2022 | |
| Glaxosmithkline, LLC. | $57.45 | 2024-2025 | Zejula, Jemperli, Blenrep |
| Pfizer INC. | $56.59 | 2024-2025 | |
| Incyte Corporation | $47.33 | 2024-2025 | Jakafi, Niktimvo |
| Array Biopharma INC | $42.10 | 2024 | Mektovi, Braftovi, Tukysa |
| Amgen INC. | $39.61 | 2024 | Prolia, Evenity |
| Geron Corporation | $33.93 | 2025 | Rytelo |
| Eisai INC. | $31.84 | 2024 | |
| Pharmaessentia USA Corporation | $31.12 | 2025 | Besremi |
| Puma Biotechnology, INC. | $29.38 | 2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $28.31 | 2024 | Padcev |
| Daiichi Sankyo INC. | $23.50 | 2024 | Enhertu |
| Springworks Therapeutics, INC. | $23.50 | 2025 | |
| Genmab U.S., INC. | $22.00 | 2024 | Epkinly |
| Emd Serono, INC. | $18.31 | 2023 | Bavencio |
| Stemline Therapeutics INC. | $16.75 | 2019 | |
| Indivior INC. | $15.69 | 2025 | Sublocade |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Glenn Wong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.